Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06458439 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. 2 versions Re-verified since Mar 26, 2025, no change to tracked fieldsv3-v4
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jul 2024 to Sep 24, 2024 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Jul 2024 to Sep 24, 2024
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.
Trial Details
NCT Number NCT06458439
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: Genmab
Conditions Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Enrollment 31 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov